Pancreatic Cancer Research

ResearcherWuhan Union HospitalNo recent work listed

Feng Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0882-5296; OpenAlex author ID A5047606978. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2021: 1 paper · 2022: 4 papers · 2023: 3 papers

Papers 8

  1. Establishment and validation of a nomogram based on coagulation parameters to predict the prognosis of pancreatic cancer. Co-author DOI 10.1186/s12885-023-10908-0↗
  2. Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study. Co-author DOI 10.1186/s40001-023-01379-x↗
  3. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. Co-author DOI 10.15252/embj.2023114558↗
  4. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. Co-author DOI 10.1002/1878-0261.13149↗
  5. FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression. Co-author DOI 10.1038/s41388-021-02140-6↗
  6. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis. First author DOI 10.1186/s13046-022-02286-5↗
  7. CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression. Co-author DOI 10.7150/ijbs.68995↗
  8. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Co-author DOI 10.1038/s41420-021-00462-8↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 6 shared papers, 2021–2023 · strength 1.09
  2. Xin Jin · 6 shared papers, 2021–2023 · strength 1.09
  3. Dianyun Ren · 3 shared papers, 2021–2023 · strength 0.54
  4. Yunpeng Peng · 2 shared papers, 2023 · strength 0.41
  5. Kai Zhang · 2 shared papers, 2023 · strength 0.41
  6. Xiang Chao Cheng · 2 shared papers, 2022 · strength 0.40
  7. Yingke Zhou · 2 shared papers, 2021–2022 · strength 0.31
  8. Li Jiaao · 1 shared paper, 2023 · strength 0.24
  9. Junpeng Meng · 1 shared paper, 2023 · strength 0.19
  10. Taoyu Chen · 1 shared paper, 2023 · strength 0.19
  11. Yan Sun · 1 shared paper, 2023 · strength 0.19
  12. Hongkun Cai · 1 shared paper, 2022 · strength 0.19
  13. Qiang Li · 1 shared paper, 2023 · strength 0.17
  14. Zipeng Lu · 1 shared paper, 2023 · strength 0.17
  15. Miao Yi · 1 shared paper, 2023 · strength 0.17
  16. Huan Zhang · 1 shared paper, 2022 · strength 0.15
  17. Yan Sun · 1 shared paper, 2022 · strength 0.15
  18. Hongkun Cai · 1 shared paper, 2022 · strength 0.15
  19. Haixin Yu · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.